Search Results for “antibody” – Page 9 – media

Haoyuan Pharmaceutical’s stock price rose by more than 150%

The cold winter of CXO has lasted for three full years since the second half of 2021. From industry leaders to emerging pharmaceutical companies, everyone has felt the chill. However, since the second half of 2024, the entire industry has shown some signs of recovery. Against the backdrop of interest rate cuts in Europe and the United States, the situation in the pharmaceutical investment and financing market has reversed, orders from many listed companies have begun to grow, and the industry turning point is about to come. Haoyuan Pharmaceutical is one of the first CXO companies to feel the warmth. Since the end of August, the stock price has risen from a low of 18.49 yuan/share to a high of 46.52 yuan/share, an increase of more than 150%. Haoyuan Pharmaceutical stock price trend Image source: Oriental Fortune What is the secret of Haoyuan Pharmaceutical behind the fluctuations in stock prices? ...
- Source: drugdu
- 31
- November 19, 2024
【EXPERT Q&A】What are the requirements for naming in vitro diagnostic reagents?

Drugdu.com expert’s response: The naming of in vitro diagnostic reagents must follow a series of clear requirements to ensure the standardization, accuracy, and ease of understanding of the names. These requirements mainly include the following points: Ⅰ. Naming Structure The product name of in vitro diagnostic reagents typically consists of three parts: Name of the Substance Being Tested: This is the target substance that the reagent detects, and the name should accurately reflect the characteristics of the substance being tested. Purpose: Describes the purpose of the reagent, such as “assay kit,” “quality control material,” etc. This part helps users understand the specific application of the reagent. Method or Principle: Explains the method or principle of the reagent’s detection, such as “magnetic bead-based chemiluminescent immunoassay,” “fluorescent PCR method,” “fluorescent in situ hybridization,” etc. This information is usually listed in parentheses to provide additional technical details. Ⅱ. Specific Naming Rules Quantitative vs. Qualitative ...
- Source: drugdu
- 42
- November 18, 2024
Global product revenue exceeds 7 billion yuan! BeiGene’s third quarter report is released

On the evening of November 12, BeiGene released its 2024 third quarter US stock performance report and A-share main financial data announcement. In the third quarter, BeiGene continued its strong growth momentum, achieving revenue of 7.139 billion yuan, a year-on-year increase of 26.9%. Global product revenue reached 7.079 billion yuan, a year-on-year increase of 65.1%. In the first three quarters of 2024, BeiGene’s total operating revenue reached 19.136 billion yuan, a year-on-year increase of 48.6%. Products continued to increase in volume at a high speed, with product revenue of 18.986 billion yuan in the first three quarters, a year-on-year increase of 72.9%. Whether it is total revenue or product revenue, the first three quarters have exceeded last year’s full-year revenue of 17.423 billion yuan, and the performance is very eye-catching. The US stock financial report shows that BeiGene’s financial situation continues to improve, with total revenue of US$1.002 billion this ...
- Source: drugdu
- 41
- November 18, 2024
Global product revenue exceeds 7 billion yuan! BeiGene’s third quarter report is released

On the evening of November 12, BeiGene released its third quarter 2024 U.S. stock performance report and A-share main financial data announcement. In the third quarter, BeiGene continued its strong growth momentum, achieving revenue of 7.139 billion yuan, a year-on-year increase of 26.9%. Global product revenue reached 7.079 billion yuan, a year-on-year increase of 65.1%. The overall performance is eye-catching . In the first three quarters of 2024, BeiGene’s total operating revenue reached 19.136 billion yuan, a year-on-year increase of 48.6%. Products continue to increase in volume at a high speed, with product revenue of 18.986 billion yuan in the first three quarters, a year-on-year increase of 72.9%. Whether it is total revenue or product revenue, the first three quarters have exceeded last year’s full-year revenue of 17.423 billion yuan, and the performance is very eye-catching. According to the U.S. stock financial report, BeiGene’s financial situation continues to improve, with ...
- Source: drugdu
- 54
- November 16, 2024
15%! AstraZeneca’s revenue in China exceeded 35 billion in the first nine months

AstraZeneca disclosed its financial report for the first three quarters of 2024 on November 12. The company’s revenue was 39.182 billion US dollars, a year-on-year increase of 19%; of which product revenue was 37.576 billion US dollars, a year-on-year increase of 19%. AstraZeneca raised its full-year performance guidance for 2024 in the announcement, and it is expected that both full-year revenue and core earnings per share will achieve high-ten-digit percentage growth, which was previously expected to be in the mid-ten digits. From the perspective of regional distribution, the Chinese market has undoubtedly become an important engine for AstraZeneca’s performance growth. In the first three quarters of 2024, AstraZeneca’s revenue in China reached more than 5 billion US dollars (equivalent to more than 35 billion yuan in RMB), accounting for about 13% of its global market share, becoming an important part of AstraZeneca’s global business. Many people may have no idea ...
- Source: drugdu
- 56
- November 15, 2024
Four innovative pharmaceutical companies have completed a new round of financing! 3 from China

According to the Instant Drug Database, last week (November 4th to November 10th), at least four emerging companies dedicated to innovative drug research and development worldwide announced the completion of a new round of financing, including three Chinese companies. These emerging companies that have gained favor in the capital market are developing drug types such as gene therapy drugs, iPSC cell therapy drugs, peptide vaccines, and antibody conjugated drugs (ADCs) with dual payloads. Kanglin Biotechnology Financing round: Series A Financing amount: 150 million yuan On November 8th, Kanglin Biotechnology (Hangzhou) Co., Ltd. (referred to as “Kanglin Biotechnology”) announced the completion of a 150 million yuan Series A financing, jointly invested by Zhejiang Province’s “4+1” Biomedical and High end Device Industry Fund and old shareholder Zhejiang Miyin Investment Management Co., Ltd. Kanglin Biology was founded in 2015, focusing on the R&D and commercialization of innovative drugs for gene therapy, targeting diseases ...
- Source: drugdu
- 54
- November 13, 2024
Domestic lupus erythematosus drugs sold for 6 billion!

According to media statistics, in the first half of 2024 alone, at least 32 innovative pharmaceutical companies in China successfully completed BD projects, achieving cross-border expansion and involving transaction amounts exceeding 20 billion US dollars, with a significant increase in quantity compared to previous years. And this trend continues into the second half of the year, with domestic innovative pharmaceutical companies such as Ruige Pharmaceutical, Jiahe Biotechnology, Tongrun Biotechnology, and Anmai Biotechnology all having significant BD transactions. Recently, a domestic innovative pharmaceutical company that has only been established for eight years and currently has only a few pipelines under research sold one of its products, BD, for a sky high price. GlaxoSmithKline (GSK) has officially announced that it has reached an acquisition agreement with Chinese innovative pharmaceutical company Chimagin Biosciences for the three specific antibody CMG1A46. Accordingly, GSK will make a prepayment of $300 million to Enmu Biotechnology to acquire ...
- Source: drugdu
- 49
- November 12, 2024
The “trend” and “newness” behind Roche Pharmaceuticals’ layout of smart healthcare in China

Never underestimate the power of the tide. “AI+ empowerment” is becoming an important engine to promote the expansion of new quality productivity in various industries, and the medical and health system is no exception. For the medical and health system, improving productivity and efficiency while reducing the cost of patients and healthcare systems is an eternal topic. This also means that the greatest potential of AI+ healthcare lies not only in the application of one or two scenarios, but in assisting and optimizing medical services in all aspects, and completely rewriting the order of all links of “diagnosis and treatment”. At this year’s CIIE, through the display of Roche, the industry leader, we can see that this trend is already very obvious: AI is penetrating in multiple dimensions to meet the individualized diagnosis and treatment needs of patients and change the direction of the tide in multiple fields. Although many ...
- Source: drugdu
- 58
- November 12, 2024
The king of cancer is to be defeated

Pancreatic cancer is known as the “king of cancer” because of its high malignancy and lack of effective drug treatment. However, the research and development community has never stopped its efforts to conquer this type of cancer. Recently, Hengrui Medicine announced that the results of the Phase III study of irinotecan liposome (II) combined with advanced pancreatic cancer were published in the Nature sub-journal “Signal Transduction and Targeted Therapy”. The results showed that the irinotecan liposome combination regimen reduced the risk of death in pancreatic cancer patients by 37% compared with the control group. In the next era beyond chemotherapy, perhaps ADC drugs will become the main force in the fight against pancreatic cancer. For example, Innovent Biologics’ ADC targeting cluadin18.2 and Lepu Bio’s ADC targeting EGFR each have their own surprises, and both have shown breakthrough efficacy in the remission rate of pancreatic cancer. In addition, Kangfang has also ...
- Source: drugdu
- 51
- November 12, 2024
Domestic bispecific antibodies win another victory

Recently, Wellizbo announced that its independently developed and globally intellectual property-owned Class 1 new drug LBL-034 has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma (MM). LBL-034 is a new generation of humanized bispecific T cell engaging antibodies targeting GPRC5D and CD3 developed using Wellizbo’s independently developed and intellectual property-owned CD3 bispecific antibody technology platform “LeadsBodyTM”. It is the third CD3 T cell connector targeting GPRC5D to enter the clinical stage in the world. Multiple myeloma (MM) is a malignant plasma cell disease caused by abnormal proliferation of clonal plasma cells, accounting for about 10% of hematological malignancies and about 1% of all tumor diseases. MM is still an incurable malignancy. With multiple lines of medication, the interval between relapses will become shorter and shorter, and eventually evolve into RRMM, which seriously threatens the life and health of patients. ...
- Source: drugdu
- 51
- November 11, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.